Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A hepatic porphyria caused by biallelic variants in ALAD (in an autosomal recessive inheritance pattern). This is an extremely rare form of hepatic porphyria characterized by neuro-visceral attacks, nausea, vomiting, diarrhea, neuropathy, and abdominal pain without cutaneous manifestations. Because the disease is so rare, inducible triggers are not well-documented.
Features include always present findings: Failure to thrive, Low muscle tone (hypotonia), Elevated urinary delta-aminolevulinic acid, and Respiratory paralysis. 9 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 2 | Vomiting, Abdominal colic |
Brain and nerves | 1 | Paresthesia |
Growth and development | 1 | Failure to thrive |
Muscles | 1 | Low muscle tone (hypotonia) |
Kidneys and urinary system | 1 | Elevated urinary delta-aminolevulinic acid |
Blood and immune system | 1 | Red blood cell destruction (hemolytic anemia) |
Lungs and breathing | 1 | Respiratory paralysis |
ALAD encodes aminolevulinate dehydratase (330 aa). Catalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen Highest expression in Adrenal Gland (189.2 TPM) and Brain Spinal cord cervical c-1 (126.5 TPM).
Porphyria due to ALA dehydratase deficiency has been associated with mutations in the ALAD gene on chromosome 9.
The ALAD protein participates in ALAD condenses 2 dALAs to form PBG and Heme biosynthesis pathways.
ALAD is classified as a druggable target (Enzyme category) with score 52.2.
Genetic testing for ALAD is available. Testing is considered supportive for diagnosis.
Biomarker and diagnostic research for porphyria due to ALA dehydratase deficiency has been reported in the published literature.
Phenotype severity distribution: 4 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
2 clinical trials registered, 1 recruiting. Interventions under study include other interventions. Research is sponsored by a mix of industry and academic institutions.
56 publications have been identified in PubMed for porphyria due to ALA dehydratase deficiency. Research spans Review / Meta-Analysis (48%), Epidemiology / Natural History (16%), and Diagnostic / Biomarker (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 27 | 48% |
Disease patterns and progression | 9 | 16% |
Testing and diagnosis research | 6 | 11% |
Laboratory research | 6 | 11% |
Patient case studies | 4 | 7% |
Clinical study results | 2 | 4% |
New treatment approaches | 2 | 4% |
Baravelli CM (2026). [PMID: 41995049](https://pubmed.ncbi.nlm.nih.gov/41995049/). *Liver Int*. [Epidemiology / Natural History]
Barman-Aksözen J (2026). [PMID: 41885813](https://pubmed.ncbi.nlm.nih.gov/41885813/). *Expert Opin Pharmacother*. [Review / Meta-Analysis]
Kothadia JP (2026). [PMID: 30725863](https://pubmed.ncbi.nlm.nih.gov/30725863/). *Unknown Journal*. [Epidemiology / Natural History]
Schedlbauer A (2026). [PMID: 41677324](https://pubmed.ncbi.nlm.nih.gov/41677324/). *Biosci Rep*. [Basic Science / Preclinical]
Mohan G (2026). [PMID: 32809671](https://pubmed.ncbi.nlm.nih.gov/32809671/). *Unknown Journal*. [Review / Meta-Analysis]
Di Pierro E (2026). [PMID: 41268747](https://pubmed.ncbi.nlm.nih.gov/41268747/). *J Intern Med*. [Basic Science / Preclinical]
Gonzalez-Mosquera LF (2026). [PMID: 31613445](https://pubmed.ncbi.nlm.nih.gov/31613445/). *Unknown Journal*. [Review / Meta-Analysis]
Musayeva G (2026). [PMID: 41857576](https://pubmed.ncbi.nlm.nih.gov/41857576/). *Orphanet J Rare Dis*. [Diagnostic / Biomarker]
Edel Y (2026). [PMID: 42069412](https://pubmed.ncbi.nlm.nih.gov/42069412/). *Lancet Haematol*. [Review / Meta-Analysis]
Dyńka D (2026). [PMID: 41486865](https://pubmed.ncbi.nlm.nih.gov/41486865/). *Ann Med*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 11:59 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center